Women's Health Clinical Trials and Research: How to Participate

Clinical trials represent the structured pathway through which new treatments, diagnostics, and preventive strategies are evaluated for safety and effectiveness before reaching broad clinical use. For women, participation in these studies carries particular significance: prior to federal policy reforms in the 1990s, women were systematically excluded from many trials, producing a research gap that affected treatment outcomes across cardiovascular disease, pharmacology, and oncology. This page explains how clinical trials are classified, how the participation process is structured, what scenarios prompt enrollment decisions, and where regulatory boundaries apply.

Definition and scope

A clinical trial, as defined by the U.S. National Institutes of Health (NIH), is a research study in human volunteers designed to answer specific health questions. Trials are distinct from observational studies in that they involve an assigned intervention — a drug, device, behavioral protocol, or procedure — rather than passive data collection.

The scope of women's health trials encompasses reproductive medicine, hormonal therapies, oncology (including breast health and ovarian cancer), cardiovascular conditions, autoimmune disorders, and mental health. The NIH Revitalization Act of 1993 mandated inclusion of women and minorities in NIH-funded clinical research, establishing a federal baseline that transformed enrollment standards across the field.

The Office of Research on Women's Health (ORWH), a component of NIH, oversees policy coordination for sex- and gender-inclusive research design. The Food and Drug Administration (FDA) classifies clinical research into interventional and observational categories, with interventional trials further divided by phase.

How it works

Clinical trials follow a four-phase structure regulated by the FDA under 21 CFR Parts 50, 56, and 312:

  1. Phase I — Tests safety, dosage range, and pharmacokinetics in a small group, typically 20 to 80 participants.
  2. Phase II — Evaluates efficacy and side effects in a larger group, typically 100 to 300 participants.
  3. Phase III — Compares the intervention against standard treatment or placebo in randomized controlled trials with groups often exceeding 1,000 participants.
  4. Phase IV — Post-market surveillance studies conducted after FDA approval to monitor long-term outcomes in the broader population.

Before enrolling, every eligible participant undergoes an informed consent process governed by the Common Rule (45 CFR Part 46), administered by the U.S. Department of Health and Human Services (HHS). Informed consent requires disclosure of the study's purpose, duration, procedures, risks, potential benefits, and the voluntary nature of participation. An Institutional Review Board (IRB) must approve trial protocols and consent documents before any enrollment begins.

Participant eligibility is defined by inclusion and exclusion criteria — the structured conditions a person must or must not meet to qualify. Criteria can include age range, disease stage, hormonal status (e.g., pre- or postmenopausal), prior treatment history, or specific biomarkers. These criteria protect participants and ensure data validity. For a fuller picture of how federal oversight structures the research environment, the regulatory context for women's health provides relevant background.

Trials are registered and publicly searchable through ClinicalTrials.gov, a database maintained by the National Library of Medicine (NLM) that lists over 400,000 studies across 220 countries as of its registry data.

Common scenarios

Women encounter clinical trial opportunities across a range of clinical settings:

The womenshealthauthority.com resource index catalogs condition-specific information across these categories for reference during pre-enrollment research.

Decision boundaries

Participation decisions involve distinct categories of consideration with meaningful structural differences:

Factor What it means Source of standards
Medical eligibility Defined by protocol inclusion/exclusion criteria Trial sponsor + FDA 21 CFR 312
Informed consent capacity Must be voluntary, competent, and documented HHS Common Rule, 45 CFR 46.116
Pregnancy status Many Phase I–II trials exclude pregnant participants; separate protections apply under Subpart B of 45 CFR 46 OHRP / HHS
Randomization and blinding Phase III trials often assign participants to active or placebo arms; double-blind designs withhold assignment from both participant and clinician FDA Guidance on Adaptive Designs
Right to withdraw Participants retain the right to discontinue at any time without penalty, as required by 45 CFR 46.116(b)(8) HHS OHRP

The comparison between therapeutic trials (which may provide direct medical benefit) and non-therapeutic trials (which contribute to knowledge without intended personal benefit) is a foundational ethical distinction established in the Belmont Report (1979), the governing ethical framework for federally regulated human subjects research.

Women with health disparities backgrounds or those relying on telehealth platforms for primary access to care may encounter access barriers to trial sites; decentralized trial designs, which allow remote participation, have been a documented area of FDA regulatory interest since the agency's 2023 Decentralized Clinical Trials Guidance.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)